ETERN is an Innovative Precision Oncology Company Focusing on Developing Novel Small Molecule Drugs to Inhibit "Undruggable" Targets, a Cutting-Edge and Highly Sought-After Area in Pharmaceutical Industry. ETERN has developed two proprietary platforms, built a strong pipeline of seven products, and advanced two lead candidates into IND-enabling stage.